How Much Weight Do You Lose Per Week on Wegovy?

Last reviewed: June 17, 2026

Last updated: June 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Weekly weight loss on semaglutide varies significantly among individuals, but clinical trials show an average loss of 1–2 pounds per week during the initial treatment phase. The actual rate depends on your baseline weight, medication dose, adherence, diet, and exercise habits. PlexusDx offers compounded semaglutide injections tailored to your body's response, at $189/mo month-to-month, or from $149/mo on the 6-month plan without insurance requirements.

Average Weekly Weight Loss Timeline on Semaglutide

Most semaglutide users experience their fastest weight loss during weeks 1–12 of treatment. During this initial phase, patients often report losing 1–2 pounds per week as the medication begins suppressing appetite and regulating blood sugar levels. This initial momentum reflects the body's adjustment to the GLP-1 receptor activation, which slows gastric emptying and increases satiety signals to the brain.

After the first three months, weekly weight loss typically plateaus to 0.5–1 pound per week. This slower rate is normal and expected; your body adapts to the medication over time, and continued weight loss becomes more gradual. Many patients continue losing weight steadily for 6–12 months before reaching a new weight equilibrium. Individual variation is substantial—some people lose more aggressively, while others experience more modest but sustainable reductions.

Total weight loss over 12 months on semaglutide averages 15–20% of body weight in clinical studies, though this range widens considerably based on patient factors. Someone starting at 250 pounds might lose 30–50 pounds in a year, while a person beginning at 200 pounds could lose 20–30 pounds. PlexusDx dosing strategies are personalized to optimize your response, ensuring you achieve meaningful results without unnecessary cost escalation—your dose may need to go up, but your price won't.

Factors That Influence Your Weekly Weight Loss Rate

Your starting weight significantly affects how quickly you lose pounds each week. Individuals with higher initial body weights often experience faster absolute weight loss in the early weeks because their bodies require more energy for baseline functions. Someone weighing 300 pounds typically loses more per week than someone weighing 200 pounds on identical semaglutide doses, partly because metabolic demand scales with body mass.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Diet quality and adherence matter substantially alongside medication. Semaglutide reduces appetite but doesn't prevent calorie consumption; eating nutrient-dense foods in moderate portions amplifies weekly weight loss compared to choosing high-calorie processed foods. Exercise frequency, sleep duration, hydration, and stress management also modulate how rapidly you shed pounds. Patients combining semaglutide with consistent physical activity and sleep optimization often outpace those relying on medication alone.

Semaglutide Dose Escalation and Weight Loss Progression

Semaglutide dosing typically follows a gradual escalation protocol, beginning at 0.25 mg weekly and increasing every 4 weeks until reaching therapeutic doses of 1.0–2.4 mg. During dose-escalation weeks, your weekly weight loss may fluctuate as your body adjusts to higher receptor activation. Some patients experience a brief plateau when their dose increases, followed by renewed weight loss momentum as tolerance develops. This pattern is expected and should not cause discouragement.

PlexusDx's pricing structure removes the financial barrier to dose optimization. Whether your therapy requires 0.5 mg, 1.5 mg, or 2.4 mg weekly, the cost remains flat at $149 per month for compounded semaglutide injection. This approach ensures you can escalate your dose based on clinical response—not affordability constraints. Your dose may need to go up to unlock faster weight loss; your price stays constant, making aggressive titration financially accessible to everyone seeking maximum results.

Real-World Weekly Loss Versus Clinical Trial Expectations

Clinical trials documenting semaglutide's efficacy enrolled carefully selected participants with consistent medication adherence, monitored diet, and regular follow-up. Real-world weight loss often falls below trial averages because actual patients juggle work, stress, variable diet quality, and medication inconsistency. A person losing 0.75 pounds per week is still making meaningful progress, even if it trails the 1–2 pound weekly average seen in controlled research settings. Setting realistic expectations prevents disappointment and supports long-term commitment to therapy.

Individual variation in weekly loss is profound and normal. Some PlexusDx patients report losing 3 pounds in week two, then only 0.5 pounds in week six, before averaging 1.5 pounds weekly over a full month. Others experience steady, predictable 1-pound losses every single week. Neither pattern indicates treatment failure; both represent successful weight reduction. Genetic factors, hormonal cycles (especially in women), medication timing, hydration status, and food choices all introduce week-to-week variation that averages out over months.

Comparing Weekly Loss: Semaglutide Injection Versus Oral Options

Injectable semaglutide (0.5–2.4 mg weekly) typically produces faster and more consistent weekly weight loss than oral semaglutide formulations (7–14 mg daily). Injection delivers the full dose directly into subcutaneous tissue, bypassing GI absorption variability and achieving higher peak plasma concentrations. Most patients lose 1–2 pounds weekly with injection during month one, compared to 0.75–1.25 pounds weekly with oral semaglutide. This difference stems from pharmacokinetics, not efficacy differences in the drug itself.

PlexusDx offers both compounded semaglutide injection ($189/month) and oral semaglutide ($289/month), allowing you to choose based on your preference and expected weight loss timeline. Injections suit patients prioritizing faster results and preferring a once-weekly commitment; oral options appeal to those who prefer daily dosing or have needle anxiety. Your prescriber can help select the format that matches your weight loss goals and lifestyle.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight do most people lose in the first week on semaglutide?

Most patients lose 0.5–2 pounds in their first week, often from reduced appetite and initial fluid shifts. Faster losses in week one don't necessarily predict sustained weekly rates; true semaglutide-driven fat loss emerges over weeks 2–4 as the medication reaches steady state. Starting PlexusDx semaglutide at $189/month lets you begin this journey immediately without membership or insurance hurdles.

Why does my weekly weight loss slow down after the first month on semaglutide?

Metabolic adaptation is normal: your body adjusts to the appetite-suppressing signal, and your metabolic rate may decrease slightly as you lose weight. Additionally, you're now losing lean tissue alongside fat, which slows absolute weight loss compared to the initial weeks of predominantly water and fat loss. Continued weekly loss of 0.5–1 pound per week for 6–12 months is still excellent progress.

Does PlexusDx charge more if I need a higher semaglutide dose for faster weight loss?

No. PlexusDx compounded semaglutide injection costs a flat $189/mo (or $149/mo on the 6-month plan) regardless of dose—whether 0.5 mg, 1.5 mg, or 2.4 mg weekly. Your dose may need to go up to optimize weight loss, but your price won't increase, making dose escalation financially accessible.

Are there side effects that slow weight loss on semaglutide?

Nausea, vomiting, or constipation in early weeks can reduce food intake beyond the medication's appetite-suppressing effect, potentially accelerating initial weight loss. However, persistent GI side effects may limit adherence or force dose reductions, potentially slowing long-term progress. Most side effects improve within 2–4 weeks. PlexusDx providers monitor your response and adjust dosing to balance efficacy with tolerability.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Wegovy For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.